ATX-002（Cat No.:I045207）is a potent small-molecule inhibitor targeting autotaxin (ENPP2), an enzyme that catalyzes the conversion of lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA), a bioactive lipid involved in cell proliferation, migration, survival, and inflammation. By blocking autotaxin activity, ATX-002 reduces LPA production, thereby modulating signaling pathways implicated in cancer progression, fibrosis, and inflammatory diseases. It is a valuable research tool for studying the autotaxin–LPA axis and its role in pathophysiology. ATX-002 holds therapeutic potential for oncology, fibrosis, and autoimmune disorders driven by dysregulated LPA signaling.